Rituximab Combined With Chidamide and Lenalidomide for r/r AITL

Inclusion Criteria

• •1. Subjects must voluntarily participate in this study and sign an informed consent.
• •2. 18-70 years old.
• •3. ECOG 0-2.
• •4. Life expectancy ≥12 weeks.
• •5. Histopathology diagnosis of AITL.
• •6. A measurable lesion (lymphoma nodule, lymph node mass or other lymphoma lesions as defined in lugano 2014) that can be measured in both diameters on the CT scan, including the longest diameter and the shortest diameter perpendicular to the longest diameter.In addition, the longest diameter of lymph nodes should be greater than 1.5cm, and the longest diameter of external lymph node lesions should be greater than 1.0cm.
• •7. The patient has received at least one line of systemic chemotherapy and currently has disease progression or treatment failure, or the patient refuses or cannot tolerate intravenous chemotherapy.
• •8. Adequate bone marrow hematopoietic function reserve and viscera function, as follows:
• •Liver function: ALT, AST≤2.5 times the normal upper limit, if there is liver metastasis, ≤5 times the normal upper limit;Total bilirubin, direct bilirubin ≤1.5 times the normal upper limit.
• •Bone marrow function (growth factor should not be used within 7 days before the first medication) : WBC ≥2.0\*109/l;The ANC acuity 1.0 \* 109 / l;PLT 50 \* 109 / l or higher;Hb 8 g/dl or higher.
• •Renal function: creatinine ≤1.5 times the normal upper limit or creatinine clearance ≥30ml/min.
• •Cardiac function: LVEF≥50%. Lung function: resting and oxygen saturation ≥95% without oxygen inhalation. Coagulation function: international standardized ratio (INR) ≤1.5×ULN and activated partial thromboplastin time (aPTT) ≤1.5×ULN, unless the patient is receiving anticoagulation therapy and the coagulation parameters (prothrombin time \[PT/INR\] and aPTT) at the time of screening are within the expected range of anticoagulant treatment.Patients whose prolongation of PT or elevation of INR resulted from the use of clotting factor inhibitors were eligible for inclusion by the investigator.